A registered study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- OBSERVATIONAL
- Evidence population
- Human clinical study registration
- Participants
- 2665
- Population
- ALL · 18 Years
- Duration
- 2020-12-20 to 2022-12-05
- Intervention
- nAMD
- Comparator
- Not reported
- Outcomes measured
- Number of patients by gender — Baseline; Age at the diagnosis — Baseline; Percentage of patients with comorbidities and concomitant procedures and medications — Baseline; Patients with unilateral or bilateral disease — Baseline; Time from diagnosis to entry to the registry — Baseline; Social Characteristics (Working and Disability status) — Baseline; Visual acuity — Baseline, up to 2 years; Presence of edema and/or neuroepithelium detachment and/or pigment epithelium detachment — Baseline, Up to 2 years; Presence of macular atrophy — Baseline, Up to 2 years; Central retinal thickness — Baseline, Up to 2 years; Fluid type — Baseline, Up to 2 years; Indication for intravitreal anti-VEGF therapy — Baseline, Up to 2 years; Type of prescribed therapy — Up to 2 years; Percentage of patients with prescription of anti-VEGF drugs — Up to 2 years; Time from diagnosis to the therapy initiation — Up to 2 years; Time from diagnosis to anti-VEGF injection — Up to 2 years; Number of visits per year — Up to 2 years; Number of anti-VEGF injections per year — Up to 2 years; Number of Optical coherence tomography (OCTs) done per year — Up to 2 years; Rate of treatment discontinuation — Up to 2 years
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.